**Supplementary Table 3. Proportion of participants with ALT normalization by the 2016\* and 2018† AASLD criteria**

|  |  |  |
| --- | --- | --- |
| **ALT normalization, *n*/*N* (%)** | **2016 AASLD criteria\*** | **2018 AASLD criteria†** |
| **TAF-TAF****(*n* = 197)** | **TDF-TAF****(*n* = 91)** | **TAF-TAF****(*n* = 197)** | **TDF-TAF****(*n* = 91)** |
| At week 48 | 126/197 (64.0%) | 47/91 (51.6%) | 139/191 (72.8%) | 58/88 (65.9%) |
| At week 96 | 137/197 (69.5%) | 49/91 (53.8%) | 153/191 (80.1%) | 57/88 (64.8%) |
| At week 144 | 141/197 (71.6%) | 58/91 (63.7%) | 159/191 (83.2%) | 66/88 (75.0%) |
| At week 192 | 130/197 (66.0%) | 64/91 (70.3%) | 147/191 (77.0%) | 70/88 (79.5%) |
| At week 240 | 134/197 (68.0%) | 63/91 (69.2%) | 154/191 (80.6%) | 68/88 (77.3%) |

﻿Missing = Failure. \*Upper limit of normal for ALT using the AASLD 2016 normal range is 19 U/L for women and 30 U/L for men; **†**Upper limit of normal for ALT using the AASLD 2018 normal range is 35 U/L for women and 25 U/L for men. AASLD, American Association for the Study of Liver Diseases; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.